Insider · CIK 0001957554

Balthaser Kevin

Reports to the SEC for 1 company · WAYNE, PA

sec.gov

Transactions

Companies

Filings

CIK

0001957554

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-03-01	ACRSAclaris Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+2,375 sh	—	—	188,130
2026-03-01	ACRSAclaris Therapeutics, Inc.F Tax Payment	Chief Financial Officer	FTax Payment	−677 sh	$2.87	−$1,942.99	187,453
2026-03-01	ACRSAclaris Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−2,375 sh	—	—	0
2026-02-03	ACRSAclaris Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+22K sh	—	—	192,204
2026-02-03	ACRSAclaris Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−22K sh	—	—	66,075
2026-02-03	ACRSAclaris Therapeutics, Inc.F Tax Payment	Chief Financial Officer	FTax Payment	−6,449 sh	$3.47	−$22.4K	185,755
2026-02-02	ACRSAclaris Therapeutics, Inc. · Employee Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+347K sh	—	—	346,800
2026-02-02	ACRSAclaris Therapeutics, Inc. · Restricted Stock UnitsA Award	Chief Financial Officer	AAward	+99.1K sh	—	—	99,100
2026-02-01	ACRSAclaris Therapeutics, Inc.F Tax Payment	Chief Financial Officer	FTax Payment	−4,984 sh	$3.51	−$17.5K	170,179
2026-02-01	ACRSAclaris Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−14.8K sh	—	—	29,500
2026-02-01	ACRSAclaris Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+14.8K sh	—	—	175,163
2026-01-02	ACRSAclaris Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−13.2K sh	—	—	13,600
2026-01-02	ACRSAclaris Therapeutics, Inc.F Tax Payment	Chief Financial Officer	FTax Payment	−4,461 sh	$2.88	−$12.8K	160,413
2026-01-02	ACRSAclaris Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+13.2K sh	—	—	164,874
2026-01-01	ACRSAclaris Therapeutics, Inc.F Tax Payment	Chief Financial Officer	FTax Payment	−2,250 sh	$3.01	−$6,772.5	151,674
2026-01-01	ACRSAclaris Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−7,500 sh	—	—	7,500
2026-01-01	ACRSAclaris Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+7,500 sh	—	—	153,924
2025-12-31	ACRSAclaris Therapeutics, Inc.F Tax Payment	Chief Financial Officer	FTax Payment	−19.9K sh	$3.01	−$60K	146,424
2025-12-31	ACRSAclaris Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−73.8K sh	—	—	0
2025-12-31	ACRSAclaris Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+73.8K sh	—	—	166,358
2025-03-01	ACRSAclaris Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+1,100 sh	—	—	90,960
2025-03-01	ACRSAclaris Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−2,375 sh	—	—	2,375
2025-03-01	ACRSAclaris Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−1,100 sh	—	—	0
2025-03-01	ACRSAclaris Therapeutics, Inc.F Tax Payment	Chief Financial Officer	FTax Payment	−727 sh	$1.99	−$1,446.73	92,608
2025-03-01	ACRSAclaris Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+2,375 sh	—	—	93,335
2025-02-03	ACRSAclaris Therapeutics, Inc. · Restricted Stock UnitsA Award	Chief Financial Officer	AAward	+88.1K sh	—	—	88,100
2025-02-03	ACRSAclaris Therapeutics, Inc. · Employee Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+308K sh	—	—	308,200
2025-02-01	ACRSAclaris Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+14.8K sh	—	—	95,676
2025-02-01	ACRSAclaris Therapeutics, Inc.F Tax Payment	Chief Financial Officer	FTax Payment	−5,816 sh	$2.48	−$14.4K	89,860
2025-02-01	ACRSAclaris Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−14.8K sh	—	—	44,250
2025-01-02	ACRSAclaris Therapeutics, Inc.F Tax Payment	Chief Financial Officer	FTax Payment	−5,059 sh	$2.48	−$12.5K	80,926
2025-01-02	ACRSAclaris Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−13.2K sh	—	—	26,800
2025-01-02	ACRSAclaris Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+13.2K sh	—	—	85,985
2025-01-02	ACRSAclaris Therapeutics, Inc. · Restricted Stock UnitsA Award	Chief Financial Officer	AAward	+40K sh	—	—	40,000
2025-01-01	ACRSAclaris Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−7,500 sh	—	—	15,000
2025-01-01	ACRSAclaris Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+7,500 sh	—	—	75,215
2025-01-01	ACRSAclaris Therapeutics, Inc.F Tax Payment	Chief Financial Officer	FTax Payment	−2,430 sh	$2.48	−$6,026.4	72,785
2024-12-31	ACRSAclaris Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+73.8K sh	—	—	98,447
2024-12-31	ACRSAclaris Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−73.8K sh	—	—	73,750
2024-12-31	ACRSAclaris Therapeutics, Inc.F Tax Payment	Chief Financial Officer	FTax Payment	−30.7K sh	$2.48	−$76.2K	67,715
2024-09-01	ACRSAclaris Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−1,000 sh	—	—	0
2024-09-01	ACRSAclaris Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+1,000 sh	—	—	24,983
2024-09-01	ACRSAclaris Therapeutics, Inc.F Tax Payment	Chief Financial Officer	FTax Payment	−286 sh	$1.18	−$337.48	24,697
2024-03-02	ACRSAclaris Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+1,500 sh	—	—	24,410
2024-03-02	ACRSAclaris Therapeutics, Inc.F Tax Payment	Chief Financial Officer	FTax Payment	−427 sh	$1.24	−$529.48	23,983
2024-03-02	ACRSAclaris Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−1,500 sh	—	—	0
2024-03-01	ACRSAclaris Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+2,375 sh	—	—	23,587
2024-03-01	ACRSAclaris Therapeutics, Inc.F Tax Payment	Chief Financial Officer	FTax Payment	−677 sh	$1.24	−$839.48	22,910
2024-03-01	ACRSAclaris Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−2,375 sh	—	—	4,750
2024-03-01	ACRSAclaris Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−1,100 sh	—	—	1,100

Recent filings

Accepted (ET)
Mar 34
Balthaser Kevin0001957554-26-000011
SEC(opens sec.gov)
Feb 64
Balthaser Kevin0001957554-26-000009
SEC(opens sec.gov)
Feb 54
Balthaser Kevin0001957554-26-000007
SEC(opens sec.gov)
Feb 34
Balthaser Kevin0001957554-26-000005
SEC(opens sec.gov)
Jan 54
Balthaser Kevin0001957554-26-000003
SEC(opens sec.gov)

Companies

Aclaris Therapeutics, Inc.Chief Financial OfficerACRS

Address

C/O ACLARIS THERAPEUTICS, INC. 701 LEE ROAD, SUITE 103

WAYNE, PA, 19087